Khaled Musallam Applauds Hatoon Ezzat’s Leadership and Healthcare Advances in Saudi Arabia
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, reposted from Thalassaemia International Federation (TIF) on LinkedIn:
”Very impressed with all the tech and regulatory advances deployed by the Ministry of Health Saudi Arabia and the leadership of Dr Hatoon Ezzat dedicated to the management of inherited blood disorders in general and thalassemia in specific. Outcomes from such initiatives will surely have global implications on disease understanding and care.”
Quoting Thalassaemia International Federation (TIF)‘s post:
”High-Level TIF–Kingdom of Saudi Arabia Strategic Meeting | 14 December 2025
A high-level delegation of the Thalassaemia International Federation – TIF held a strategic meeting on 14 December 2025 with senior representatives of the Ministry of Health Saudi Arabia, underscoring a shared commitment to accelerating progress in the prevention, control, and comprehensive management of thalassaemia and other haemoglobinopathies.
The TIF delegation comprised Dr. Androulla Eleftheriou, TIF Executive Director; Prof. john porter, Professor of Haematology and Consultant Haematologist at University College London Hospitals (UK); Prof. Khaled Musallam, MD, PhD, Group Chief Research Officer of Burjeel Holdings and Founding Director of CR-RBD (UAE); and Prof. Dimitrios Farmakis, MD, PhD, FESC, FHFA, Professor of Cardiology at the National and Kapodistrian University of Athens (Greece), members of TIF’s International Scientific Advisory Board.
The delegates met with H.E. Dr. Mohammed K. Alabdulaali, Assistant Deputy Minister for Hospital Services; Dr. Hatoon Ezzat, Assistant Minister’s Advisor and General Supervisor of Blood Disorders; and Prof. Ahmad Tarawah, Consultant in Pediatric Hematology/Oncology.
During the discussions, TIF congratulated the Government of the KSA on its notable progress in strengthening national systems for the control and management of thalassaemia and other haemoglobinopathies, as well as on the impressive outcomes of its health-sector digitaltransformation.
Particular emphasis was placed on advancing integrated digital health ecosystems and strengthening datasystems, enabling smarter service planning, better follow-up, improved continuity of care, and a more streamlined patientjourney across different levels of the health system.
TIF also commended the KSA’s leadership in facilitating access to healthinnovation, including its distinction as the first country globally to authorise the novel oral therapy PYRUKYND® (mitapivat) for adult patients with transfusion-dependent (TDT) and non-transfusion-dependent (NTDT) α- or β-thalassaemia.
Building on an already excellent and long-standing collaboration between TIF and the KSA, the meeting also explored a forward-looking agenda of joint initiatives.
These include co-developed educational activities and collaborative actions that could support regional and international efforts to improve standards of care and outcomes for patients and their families.”
Stay updated with Hemostasis Today.
-
Aug 31, 2026, 17:11Chokri Ben Lamine: Early Recognition and Immediate Treatment of Catastrophic APS
-
Aug 31, 2026, 17:06Nikolaos Ktenopoulos: COMPASS-ARTeCAT Trial Highlights Arterial Thrombosis in Patients With Cancer
-
Aug 31, 2026, 17:01Mark Kaplan: Same LDL-C, Different Coagulation, Different Outcomes, in FH
-
Aug 31, 2026, 16:55Kemal Karaagac: Milvexian Did Not Reduce Ischemic Events but Did Not Increase Fatal Bleeding
-
Aug 31, 2026, 16:47Improving Outcomes in AF-Related Stroke Beyond Anticoagulation at ESC 2026 – ESO
-
Aug 31, 2026, 16:39Shariq Shamim: Are We Going to Start DOAC post TAVI not DAPT?
-
Aug 31, 2026, 16:30Bartosz Hudzik: 5th Universal MI Definition Moves Closer to Biology in Women
-
Aug 31, 2026, 16:13Seema Dawood: Nucleated Red Blood Cells – What They Tell Us on a Peripheral Smear
-
Aug 31, 2026, 16:02Antonio Sorropago: Major Updates in Structural Heart Interventions